| Autor: |
Fournier, Christina N., Glass, Jonathan D. |
| Předmět: |
|
| Zdroj: |
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration; Feb2024, Vol. 25 Issue 1/2, p216-217, 2p |
| Abstrakt: |
This article responds to a critique of a study that aimed to calculate the minimal important difference (MID) for the revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R). The authors clarify that the MID was not intended to determine the success of clinical trials or be used as a cutoff value for individual treatment decisions. Instead, it provides a framework for patients and clinicians to understand research results and disease progression. The study included a diverse group of ALS patients, allowing for a broader understanding of the MID's application in clinical decision-making. The authors argue against relying solely on expert opinion and emphasize the importance of considering patient-defined parameters of clinical meaningfulness. They acknowledge the limitations of their study, such as the potential for recall bias and the need for more frequent assessments. Despite these limitations, the authors maintain that calculating a patient-driven MID for the ALSFRS-R is valuable in providing clinical context and understanding disease progression and treatment response. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
